Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., explained in plain language.
Biopharmaceutical company focused on antibody-drug conjugates (ADCs) and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo aims to slow advanced lung cancer in first-line trial Results expected Nov 2026 (estimated)
- New hope for advanced breast cancer: A166 takes on T-DM1 in head-to-head trial Results expected Nov 2026 (estimated)
- New hope for lung cancer patients who can't use standard immunotherapy alone Results expected Dec 2026 (estimated)
- New cancer drug SKB571 enters first human tests Results expected Dec 2026 (estimated)
- New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial Results expected Dec 2026 (estimated)
-
New pill shows promise for severe baldness, but trial cut short
Disease control Stopped earlyThis study tested a drug called KL130008 in 114 adults with severe alopecia areata, a condition causing major hair loss. The goal was to see if the drug could safely regrow hair, measured by how many people achieved 80% or more scalp coverage. However, the trial was terminated ea…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental cancer drug combo trial halted early
Disease control Stopped earlyThis phase 3 trial tested a drug called A140 (similar to cetuximab) combined with chemotherapy (mFOLFOX6) as a first treatment for people with a specific type of advanced colorectal cancer (RAS wild-type). The study planned to enroll 570 people in China but was terminated early w…
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC